AbbVie to acquire Apogee Therapeutics, updates 2026 EPS guidance amid Q2 results

AbbVie disclosed on July 31, 2026 that it has signed a definitive agreement to acquire Apogee Therapeutics and its pipeline of clinical-stage candidates in inflammatory and immunological diseases, including zumilokibart (APG777), a late-stage monoclonal antibody targeting IL-13 for atopic dermatitis, and APG273, a combination candidate targeting IL-13 and TSLP in asthma.¹ The deal is expected to close in the third quarter of 2026 and values Apogee at a total equity value of approximately $10.9 billion.¹

As a result, AbbVie updated its adjusted diluted EPS guidance to reflect an anticipated $0.14 per share dilutive impact from the pending Apogee acquisition, moving the full-year 2026 range from $13.91-$14.11 to $13.87-$14.07.¹ The company said this dilution is partially offset by $0.10 of overperformance.¹ Guidance also includes a $0.58 per share unfavorable impact from acquired IPR&D and milestones expense incurred year-to-date through the second quarter, and excludes any such expense that may occur after that period, since it cannot be reliably forecast.¹

Regulatory activity was extensive in the quarter. The FDA and European Commission approved Skyrizi for children six and older with moderate to severe plaque psoriasis, and the FDA separately approved it for pediatric psoriatic arthritis, based on the Phase 3 OptIMMize program.¹ The EC also approved Rinvoq for adult and adolescent non-segmental vitiligo, making it the first systemic EU-approved medicine for that condition,¹ and approved Rinvoq for severe alopecia areata based on the Phase 3 UP-AA program.¹

In oncology, the FDA approved Decnupaz (pivekimab sunirine) for adult BPDCN, an ultra-rare hematologic malignancy, based on Phase 1/2 CADENZA trial data.¹ The EC granted marketing authorization for Tepkinly in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, based on the Phase 3 EPCORE FL-1 trial.¹ AbbVie also reported topline Phase 3 EPCORE DLBCL-4 results showing Epkinly plus lenalidomide produced statistically significant and clinically meaningful progression-free survival improvement¹ versus a chemotherapy comparator, the company said.